Search

GPs could take a more active role in suggesting them

Showing "11154" results for ""

CMV antiviral may reduce inflammation and improve immune function in people with HIV

Manufacturer’s plans for equitable access to twice-yearly PrEP under fire

Few people with HIV in England starting statins despite new recommendations

Climate change is threatening the sexual health of young adolescents in Kenya

Women with HIV have no cardiovascular advantage over men, unlike in the general population

Two doses of HPV vaccine as effective as the recommended three-dose schedule for women with HIV

Are automated campaigns driven by AI the future of HIV prevention?

Coming soon: news from IAS 2025

Rwanda’s HIV leadership on display at IAS 2025

“We will not go back!”: a powerful, resolute response to funding cuts at IAS 2025

Resistance is a growing concern amid rising use of doxyPEP

Engineered T-cells may kill off reservoir cells, mimicking elusive CD8 vaccine effect

Once-monthly oral PrEP moves into late-stage trials

Treatment changes do not reduce weight in people with HIV

Scaling back PEPFAR will leave 700,000 without PrEP and cause 6700 new HIV infections within a year

Intermittent HIV treatment dosing may be a response to the funding crisis, but adolescent study raises concerns

Injectable HIV treatment works for people with poor HIV control in Africa

Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding

Receive the latest HIV research and conference news

Showing "11154" results for ""

CMV antiviral may reduce inflammation and improve immune function in people with HIV

Manufacturer’s plans for equitable access to twice-yearly PrEP under fire

Few people with HIV in England starting statins despite new recommendations

Climate change is threatening the sexual health of young adolescents in Kenya

Women with HIV have no cardiovascular advantage over men, unlike in the general population

Two doses of HPV vaccine as effective as the recommended three-dose schedule for women with HIV

Are automated campaigns driven by AI the future of HIV prevention?

Coming soon: news from IAS 2025

Rwanda’s HIV leadership on display at IAS 2025

“We will not go back!”: a powerful, resolute response to funding cuts at IAS 2025

Resistance is a growing concern amid rising use of doxyPEP

Engineered T-cells may kill off reservoir cells, mimicking elusive CD8 vaccine effect

Once-monthly oral PrEP moves into late-stage trials

Treatment changes do not reduce weight in people with HIV

Scaling back PEPFAR will leave 700,000 without PrEP and cause 6700 new HIV infections within a year

Intermittent HIV treatment dosing may be a response to the funding crisis, but adolescent study raises concerns

Injectable HIV treatment works for people with poor HIV control in Africa

Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding

Receive the latest HIV research and conference news